The MDPI Magazine Finds a New Home

The MDPI magazine has merged with the recently launched MDPI blog. Through this combined service, we will continue to provide information about the most interesting articles published in our open access journals alongside updates and innovations to our publishing platform. This site will remain available, but new posts will be added at the blog.

Thank you for your readership, and we look forward to welcoming you on the new platform, where we will continue to share the latest research knowledge in an open and accessible way.

Finding the Best Fit: Bayesian Statistics Meets Geometry


Guest Commentary by Dr. Martyn Rittman

A common problem faced in research is when a set of data has been collected on the one hand, and a theoretical model (a set of equations with input parameters) exists on the other. We want to know firstly, whether the model describes the data well and secondly, what variables of the model give the best possible fit.

Continue reading

HCMV Vaccine Development Targets Immunomodulatory Proteins

Guest Commentary by Anamaris Colberg-Poley*


Human cytomegalovirus (HCMV) can cause severe disease in immunocompromised individuals and in congenitally infected infants, thus the development of an HCMV vaccine has been a national priority over the last few decades.  Despite attempts similar to those which have proven successful for other herpesviruses, such as varicella zoster virus, attenuated HCMV vaccine strains (such as Towne) have not been analogously successful as effective HCMV vaccines. Continue reading

Towards Therapeutic Use of Antimicrobial Peptides: Conferring Cell Selectivity by Introducing Specificity Determinants


Guest Commentary by Guangshun Wang*

We are living in an era of antibiotic resistance; fortunately, there is widespread recognition of the consequences of this dilemma. While scientists have long been fascinated by the impressive diversity of antimicrobial peptides (also called host defense peptides) that exist in bacteria, protozoa, fungi, plants, and animals, there is a current urgency to explore novel strategies to make use of these compounds as therapeutic antimicrobials. However, while these peptides can exhibit a broad spectrum of antimicrobial activity, their potential toxicity in systemic administration has represented a significant challenge for medicinal use.  Continue reading

Monoclonal Antibody to HCMV Glycoprotein B Blocks Viral Entry and Growth in Trophoblast Progenitor Cells

Guest Commentary by Anamaris Colberg-Poley*


Human cytomegalovirus (HCMV) is the major cause of congenital birth infections in developed countries.  HCMV can cause severe birth defects including microcephaly, mental retardation, sensorineural hearing loss, and intrauterine growth restriction. However, because of the potential for teratogenicity and toxic effects, no therapeutic treatment is currently approved by the Food and Drug Administration for congenital HCMV infection. The studies by Lenore Pereira and her colleagues (Zydek et al., 2014.  Viruses  Special Issue on Recent CMV Research) have significant implications for developing therapies for treatment of congenital HCMV infections, which are seriously lacking at this time. Continue reading